- Theratechnologies Inc. (TH) presents new in vivo preclinical data for TH1902 candidate demonstrating tumour growth inhibition in breast and ovarian cancers
- It examined the efficacy of TH1902 against cancer stem-like cells and to evade known drug resistance phenotypes
- TH19P01 was exhibited in both cancer stem cell (CSC) lines inhibited suggesting that the peptide is highly targeted to protein expression which is absent in healthy cells
- An 80 per cent decrease in tumour growth was observed in TH1902
- Theratechnologies Inc. (TH) is down 0.34 per cent trading at $2.92 per share as of 2:33 p.m. ET
Theratechnologies (TH) has presented new in vivo preclinical data for the TH1902 candidate demonstrating tumour growth inhibition in breast and ovarian cancers.
The study examined the efficacy of TH1902 against cancer stem-like cells and its ability to evade some of the known drug resistance phenotypes associated with CSCs.
Uptake of TH19P01 was exhibited in both cancer stem-like cell lines but was inhibited suggesting that the peptide is highly targeted to protein expression which is absent in healthy cells.
TH1902 induced a marked increase in cell death and produced cell cycle arrest and did not affect healthy tissue. It also significantly inhibited the growth of cancer stem-like cell tumours when administered weekly for three cycles and treated mice exhibited increased tolerability. As a single agent in breast and ovarian cancer stem-like cell xenograft tumour models, TH1902 showed better efficacy as compared to docetaxel alone. Better efficacy was also observed in the ovarian tumour model for the TH1902-carboplatin combination.
An 80 per cent decrease in tumour growth was observed in TH1902. The results demonstrated that TH1902 exerts superior anticancer activity in CD133+ triple-negative breast and ovarian cancer stem-like cell animal models.
Theratechnologies Inc. (TH) is down 0.34 per cent trading at $2.92 per share as of 2:33 p.m. ET.
